As pharma marketers, we tend to listen closely when the U.S. Food and Drug Administration (FDA) issues guidance, such as their draft guidance on correcting misinformation online, and user-generated content. In June this year, however, it was guidelines from the Federal Trade Commission (FTC) that got our attention. The updates